经肝动脉化疗栓塞术、经门静脉化疗栓塞术联合高强度聚焦超声治疗门静脉癌栓的临床研究

发布时间：2018-06-16 18:14

本文选题：原发性肝癌 + 门静脉癌栓　；参考：《介入放射学杂志》2015年03期

【摘要】：目的观察经肝动脉化疗栓塞术(TACE)、经门静脉化疗栓塞术(PVE)联合高强度聚焦超声(HIFU)治疗原发性肝癌合并门静脉癌栓的临床疗效。方法分析2011年1月至2012年2月收治的原发性肝癌合并门静脉癌栓患者85例,TACE、PVE联合HIFU治疗47例为观察组,TACE、PVE治疗38例为对照组,TACE治疗后2周行PVE,PVE后10 d左右行HIFU治疗。结果观察组的近期有效率为89.4%(42/47),对照组为39.5%(15/38),两组比较差异有统计学意义(P0.05)。观察组6个月、1年、2年的生存率为87.2%(41/47)、66.0%(31/47)、27.7%(13/47),中位生存期15.4个月,对照组上述时间点生存率分别为55.3%(21/38)、39.5%(15/38)和10.5%(4/38),中位生存期10.3个月,两组比较差异有统计学意义(P0.05)。结论 TACE、PVE联合HIFU治疗原发性肝癌门静脉癌栓可显著提高疗效,延长生存时间,是一种较为安全、有效的治疗方法。
[Abstract]:Objective to observe the clinical effect of transcatheter arterial chemoembolization (TACEE) and portal vein chemoembolization (PVE) combined with high intensity focused ultrasound (HIFU) in the treatment of primary liver cancer with portal vein tumor thrombus. Methods from January 2011 to February 2012, 85 patients with primary liver cancer complicated with portal vein cancer thrombus were treated with TACEE PVE combined with HIFU. 47 cases were treated with TACEE PVE in the observation group. 38 cases in the control group were treated with HIFU about 10 days after PVE. Results the short-term effective rate of the observation group was 89.4 / 42 / 47 and the control group was 39.5 / 38. The difference between the two groups was statistically significant (P 0.05). The 6-month, 1-year and 2-year survival rates of the observation group were 87.2 / 41 / 47 / 66.0 and 27.71 / 47, with a median survival time of 15.4 months. The survival rates at these time points in the control group were 55.3N / 2138 / 39.595 / 38 and 10.555 / 43.38%, respectively. The median survival period was 10.3 months. The difference between the two groups was statistically significant (P 0.05). Conclusion TACE-PVE combined with HIFU is a safe and effective method for the treatment of portal vein cancer thrombus of primary liver cancer.
【作者单位】：山东省肿瘤医院特检科;山东省济南市第二人民医院;
【分类号】：R735.7;R445.1

【参考文献】